246 related articles for article (PubMed ID: 27839685)
21. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.
Osborne RJ; Lin X; Welle S; Sobczak K; O'Rourke JR; Swanson MS; Thornton CA
Hum Mol Genet; 2009 Apr; 18(8):1471-81. PubMed ID: 19223393
[TBL] [Abstract][Full Text] [Related]
23. Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Warf MB; Nakamori M; Matthys CM; Thornton CA; Berglund JA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18551-6. PubMed ID: 19822739
[TBL] [Abstract][Full Text] [Related]
24. Expanded CUG repeats Dysregulate RNA splicing by altering the stoichiometry of the muscleblind 1 complex.
Paul S; Dansithong W; Jog SP; Holt I; Mittal S; Brook JD; Morris GE; Comai L; Reddy S
J Biol Chem; 2011 Nov; 286(44):38427-38438. PubMed ID: 21900255
[TBL] [Abstract][Full Text] [Related]
25. Precise small-molecule recognition of a toxic CUG RNA repeat expansion.
Rzuczek SG; Colgan LA; Nakai Y; Cameron MD; Furling D; Yasuda R; Disney MD
Nat Chem Biol; 2017 Feb; 13(2):188-193. PubMed ID: 27941760
[TBL] [Abstract][Full Text] [Related]
26. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.
Pushechnikov A; Lee MM; Childs-Disney JL; Sobczak K; French JM; Thornton CA; Disney MD
J Am Chem Soc; 2009 Jul; 131(28):9767-79. PubMed ID: 19552411
[TBL] [Abstract][Full Text] [Related]
27. The Dimeric Form of 1,3-Diaminoisoquinoline Derivative Rescued the Mis-splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Type 1 Mouse Model.
Matsumoto J; Nakamori M; Okamoto T; Murata A; Dohno C; Nakatani K
Chemistry; 2020 Nov; 26(63):14305-14309. PubMed ID: 32449537
[TBL] [Abstract][Full Text] [Related]
28. Dynamic docking of small molecules targeting RNA CUG repeats causing myotonic dystrophy type 1.
Wang KW; Riveros I; DeLoye J; Yildirim I
Biophys J; 2023 Jan; 122(1):180-196. PubMed ID: 36348626
[TBL] [Abstract][Full Text] [Related]
29. Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy.
Nakamori M; Taylor K; Mochizuki H; Sobczak K; Takahashi MP
Ann Clin Transl Neurol; 2016 Jan; 3(1):42-54. PubMed ID: 26783549
[TBL] [Abstract][Full Text] [Related]
30. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.
Li M; Zhuang Y; Batra R; Thomas JD; Li M; Nutter CA; Scotti MM; Carter HA; Wang ZJ; Huang XS; Pu CQ; Swanson MS; Xie W
Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5472-5477. PubMed ID: 32086392
[TBL] [Abstract][Full Text] [Related]
31. A Ligand That Targets CUG Trinucleotide Repeats.
Li J; Matsumoto J; Bai LP; Murata A; Dohno C; Nakatani K
Chemistry; 2016 Oct; 22(42):14881-14889. PubMed ID: 27573860
[TBL] [Abstract][Full Text] [Related]
32. Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats.
Arandel L; Matloka M; Klein AF; Rau F; Sureau A; Ney M; Cordier A; Kondili M; Polay-Espinoza M; Naouar N; Ferry A; Lemaitre M; Begard S; Colin M; Lamarre C; Tran H; Buée L; Marie J; Sergeant N; Furling D
Nat Biomed Eng; 2022 Feb; 6(2):207-220. PubMed ID: 35145256
[TBL] [Abstract][Full Text] [Related]
33. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G
Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640
[TBL] [Abstract][Full Text] [Related]
34. A Small Molecule that Binds an RNA Repeat Expansion Stimulates Its Decay via the Exosome Complex.
Angelbello AJ; Benhamou RI; Rzuczek SG; Choudhary S; Tang Z; Chen JL; Roy M; Wang KW; Yildirim I; Jun AS; Thornton CA; Disney MD
Cell Chem Biol; 2021 Jan; 28(1):34-45.e6. PubMed ID: 33157036
[TBL] [Abstract][Full Text] [Related]
35. Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1.
Chen CZ; Sobczak K; Hoskins J; Southall N; Marugan JJ; Zheng W; Thornton CA; Austin CP
Anal Bioanal Chem; 2012 Feb; 402(5):1889-98. PubMed ID: 22218462
[TBL] [Abstract][Full Text] [Related]
36. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
37. Features of modularly assembled compounds that impart bioactivity against an RNA target.
Rzuczek SG; Gao Y; Tang ZZ; Thornton CA; Kodadek T; Disney MD
ACS Chem Biol; 2013 Oct; 8(10):2312-21. PubMed ID: 24032410
[TBL] [Abstract][Full Text] [Related]
38. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy.
Du H; Cline MS; Osborne RJ; Tuttle DL; Clark TA; Donohue JP; Hall MP; Shiue L; Swanson MS; Thornton CA; Ares M
Nat Struct Mol Biol; 2010 Feb; 17(2):187-93. PubMed ID: 20098426
[TBL] [Abstract][Full Text] [Related]
39. A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.
Luu LM; Nguyen L; Peng S; Lee J; Lee HY; Wong CH; Hergenrother PJ; Chan HY; Zimmerman SC
ChemMedChem; 2016 Jul; 11(13):1428-35. PubMed ID: 27245480
[TBL] [Abstract][Full Text] [Related]
40. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats.
Kino Y; Mori D; Oma Y; Takeshita Y; Sasagawa N; Ishiura S
Hum Mol Genet; 2004 Mar; 13(5):495-507. PubMed ID: 14722159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
